DBV Technologies S.A. (NASDAQ:DBVT) Receives $48.50 Consensus Price Target from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $48.50.

A number of analysts recently weighed in on DBVT shares. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Citizens Jmp increased their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Guggenheim reiterated a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a research report on Monday, May 4th.

DBV Technologies Stock Down 7.6%

DBVT stock opened at $16.75 on Friday. DBV Technologies has a fifty-two week low of $8.50 and a fifty-two week high of $26.18. The firm’s 50-day simple moving average is $19.27 and its 200 day simple moving average is $19.74. The stock has a market cap of $991.73 million, a PE ratio of -3.76 and a beta of -0.99.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $1.11 million. Equities analysts forecast that DBV Technologies will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP bought a new position in DBV Technologies in the 4th quarter valued at about $32,000. Royal Bank of Canada bought a new position in DBV Technologies in the 4th quarter valued at about $34,000. GAMMA Investing LLC grew its position in DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after buying an additional 744 shares in the last quarter. New York State Common Retirement Fund bought a new position in DBV Technologies in the 3rd quarter valued at about $34,000. Finally, Truvestments Capital LLC grew its position in DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares in the last quarter. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.